- 专利标题： USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES
-
申请号： PCT/EP2021/069834申请日： 2021-07-15
-
公开(公告)号： WO2022017926A1公开(公告)日： 2022-01-27
- 发明人: CHECKETTS, Daniel, Adam , CRAIG, Kevin, James
- 申请人： GW RESEARCH LIMITED
- 申请人地址： Sovereign House Vision Park, Chivers Way
- 专利权人： GW RESEARCH LIMITED
- 当前专利权人： GW RESEARCH LIMITED
- 当前专利权人地址： Sovereign House Vision Park, Chivers Way
- 代理机构： CHEETHAM, Emma, Louise
- 优先权： GB2011127.4 2020-07-20
- 主分类号： A61K31/05
- IPC分类号： A61K31/05 ; A61K31/4015 ; A61K31/195 ; A61K31/551 ; A61K31/4166 ; A61K31/7048 ; A61K45/06 ; A61P25/08 ; A61P25/12
摘要：
The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with PCDH19 Epilepsy. In a further embodiment the types of seizures include tonic-clonic seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.
